To include your compound in the COVID-19 Resource Center, submit it here.

Ab's dry (AMD) humor

A collaborative effort by Pfizer Inc. and U.S. academicshas found that immunotherapy against beta-amyloid can reverse the retinal protein deposition that leads to dry age-related macular degeneration. The finding could open up a repurposing opportunity for mAbs in development for Alzheimer's disease.1

"We've established beta-amyloid as a therapeutic target for dry AMD," a thus far untreatable form of the disease, said team leader Catherine Bowes Rickman, associate professor of ophthalmology and cell biology at Duke University.

Bowes Rickman's team built on prior

Read the full 806 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE